Literature DB >> 29557943

Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?

Laura Targownik1.   

Abstract

Proton pump inhibitors (PPIs) are among the most widely used class of drugs prescribed over the long term in all of clinical medicine with 8-10% of ambulatory adults have been prescribed a PPI in the past 30 days. However, numerous studies have raised doubts about the long term safety of PPI use. The purpose of this review is threefold: (i) To provide an overview of the current evidence demonstrating associations between PPI use and adverse health outcomes and the likelihood of the associations being causal (Why?); (ii) To be able to identify long-term PPI users in whom the intensity of PPI therapy could be reduced or in whom PPIs could be eliminated outright (Who?); and (iii) To provide strategies on how to reduce or stop chronic PPI therapy while maintaining symptom control and reducing the risk for symptom or upper GI disease recurrence (How?).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29557943     DOI: 10.1038/ajg.2018.29

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  109 in total

Review 1.  Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors.

Authors:  Daniel Sifrim; Frank Zerbib
Journal:  Gut       Date:  2012-06-08       Impact factor: 23.059

2.  Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users.

Authors:  Mitchell H Katz
Journal:  Arch Intern Med       Date:  2010-05-10

3.  Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial.

Authors:  Matthew J Wright; Rebecca R Sullivan; Erin Gaffney-Stomberg; Donna M Caseria; Kimberly O O'Brien; Deborah D Proctor; Christine A Simpson; Jane E Kerstetter; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

4.  Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.

Authors:  John M Inadomi; Lisa McIntyre; Latoya Bernard; A Mark Fendrick
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

Review 5.  Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis.

Authors:  S B Jung; V Nagaraja; A Kapur; G D Eslick
Journal:  Intern Med J       Date:  2015-04       Impact factor: 2.048

Review 6.  Proton pump inhibitors for functional dyspepsia.

Authors:  Maria Ines Pinto-Sanchez; Yuhong Yuan; Premysl Bercik; Paul Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2017-03-08

Review 7.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

8.  Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.

Authors:  Derk C F Klatte; Alessandro Gasparini; Hong Xu; Pietro de Deco; Marco Trevisan; Anna L V Johansson; Björn Wettermark; Johan Ärnlöv; Cynthia J Janmaat; Bengt Lindholm; Friedo W Dekker; Josef Coresh; Morgan E Grams; Juan J Carrero
Journal:  Gastroenterology       Date:  2017-06-02       Impact factor: 22.682

9.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

10.  Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.

Authors:  Nigam H Shah; Paea LePendu; Anna Bauer-Mehren; Yohannes T Ghebremariam; Srinivasan V Iyer; Jake Marcus; Kevin T Nead; John P Cooke; Nicholas J Leeper
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

View more
  4 in total

1.  Comparison of the prevalence and nature of potentially inappropriate medication use in geriatric outpatients between tertiary and community healthcare settings: a multicenter cross-sectional study.

Authors:  Yan Zeng; Yongpei Yu; Qingyang Liu; Su Su; Yang Lin; Hongyan Gu; Shicai Chen; Pengmei Li; Tong Xu; Naizhao Sun; Tao Lin; Qian Huang; Yujie Fan; Fengzhi Wang; Suying Yan
Journal:  Int J Clin Pharm       Date:  2022-02-25

2.  Reflux Symptoms: Functional and Structural Diseases and the Approach from the GI Specialist.

Authors:  Lars Lundell
Journal:  Dig Dis       Date:  2021-02-09       Impact factor: 2.404

3.  Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey.

Authors:  Jacob E Kurlander; Joel H Rubenstein; Caroline R Richardson; Sarah L Krein; Raymond De Vries; Brian J Zikmund-Fisher; Yu-Xiao Yang; Loren Laine; Arlene Weissman; Sameer D Saini
Journal:  Am J Gastroenterol       Date:  2020-05       Impact factor: 12.045

4.  Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.

Authors:  Jennifer S Davis; Preeti Kanikarla-Marie; Mihai Gagea; Patrick L Yu; Dexing Fang; Manu Sebastian; Peiying Yang; Ernest Hawk; Roderick Dashwood; Lenard M Lichtenberger; David Menter; Scott Kopetz
Journal:  BMC Cancer       Date:  2020-09-10       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.